Dulaglutide vs Efinopegdutide

Head-to-head comparison of Dulaglutide (Recombinant GLP-1 receptor agonist Fc fusion protein) and Efinopegdutide (Efinopegdutide (HM12525A), long-acting glucagon-like peptide-1/glucagon receptor dual agonist) — benefits, dosing, side effects, research data, and where to buy.

Research Score

PropertyDulaglutideEfinopegdutide
CategoryWeight ManagementWeight Management
Full NameRecombinant GLP-1 receptor agonist Fc fusion proteinEfinopegdutide (HM12525A), long-acting glucagon-like peptide-1/glucagon receptor dual agonist
Molecular Weight~63,000 DaN/A
Half-LifeAbout 5 daysApproximately 1 week
Amino AcidsN/AN/A
Typical Dose0.75-4.5 mg weeklyTrial-dependent; weekly SC dosing
RouteSubcutaneousSubcutaneous
Purity≥98%≥98%
Studies Count70014
Research StatusApprovedClinical

Dulaglutide Benefits

  • modest weight loss
  • lower A1c
  • weekly dosing convenience
  • cardiometabolic benefit

Efinopegdutide Benefits

  • reduced body weight
  • improved insulin sensitivity
  • reduced liver fat
  • greater satiety

Dulaglutide Dosing

0.75-4.5 mg SC weekly|Increase based on response and tolerance|Administer on the same day each week

Efinopegdutide Dosing

once-weekly subcutaneous injection|dose escalation during lead-in|maintenance dosing in trials

Dulaglutide Side Effects

  • nausea
  • diarrhea
  • injection-site reactions

Efinopegdutide Side Effects

  • nausea
  • decreased appetite
  • fatigue

Research Overview

Dulaglutide

Dulaglutide has repeatedly shown small-to-moderate reductions in body weight alongside glycemic improvement in large diabetes trials. It is a useful comparator for GLP-1 receptor agonist effects on appetite and weight.

Efinopegdutide

Human trials have shown meaningful weight loss and improvements in hepatic steatosis biomarkers. It remains a research compound with ongoing development in metabolic disease.

Ready to buy?

Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.

Common Stacking Partners

Dulaglutide stacks with:

metformindiet-and-exercise

Efinopegdutide stacks with:

metforminorlistat
GLP-1RAweekly-injectiontype-2-diabetesmodest-weight-lossglp1glucagondual-agonistobesitynash